Adocia (LTS:0QAI) Tariff Resilience Score: 0/10 (As of Jul. 02, 2026)


LTS:0QAI Adocia LTS:0QAI
35 GF Score
Price €4.13
GF Value €0.89
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Adocia Tariff Resilience Score?

Adocia has the Tariff Resilience Score of 0, which implies that the company might have .

Adocia has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Adocia might have .

Adocia  (LTS:0QAI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Adocia Tariff Resilience Score Related Terms

LTS:0QAI
35GF Score
Adocia LTS:0QAI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adocia (LTS:0QAI) Overvalued in 2026?

Based on GuruFocus' analysis, Adocia stock appears to be overvalued. The current stock price of €4.13 is trading 363.6% above its estimated GF Value™ of €0.89. GuruFocus considers Adocia to be Significantly Overvalued.

Key valuation signals for LTS:0QAI:

  • Tariff Resilience Score: 0
  • GF Value™: €0.89 vs. price of €4.13 (363.6% above fair value)
  • GF Score™: 35/100 with 7 warning signs

No single metric tells the full story. See the LTS:0QAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adocia Business Description

Other Exchanges ADOC:FranceA89:Germany
Address 115 Avenue Lacassagne, Lyon, FRA, 69003
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
35GF Score

Get the complete analysis for LTS:0QAI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.13
Price
€0.89
GF Value